The government has been spraying a chemical from the air in Kamloops, the Okanagan and around the province to combat the ...

Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations ...

Video content above is prompted by the following: The ASH abstract by Mansour and colleagues suggests that for patients who have been on BTK inhibitors for more than 2 years, discontinuing therapy ...

Credit: Nadezhda Fedrunova via Getty Images. AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Caterpillar is committed to ensuring our workplace is diverse and representative of the many customers we serve around the globe. Caterpillar's strategy and purpose outline where we're headed and why ...

Read corporate press releases and news announcements distributed by Caterpillar Inc. Taxes, shipping & handling, surcharges, assembly charges, destination, freight and/or delivery charges are not ...

January 16, 2025—Concept Medical Inc., announced the enrollment of the first patient in the pivotal MAGICAL BTK randomized controlled trial, which is being conducted in the United States under an ...

COOMBS: We have so many effective therapies that it is often difficult to choose. Bruton tyrosine kinase [BTK] inhibitors are the mainstay in CLL, with ibrutinib [Imbruvica] being the first approved, ...